Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 1.3% – Should You Sell?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) dropped 1.3% during mid-day trading on Thursday . The stock traded as low as $7.97 and last traded at $8.24. Approximately 8,988,098 shares traded hands during mid-day trading, a decline of 65% from the average daily volume of 25,388,480 shares. The stock had previously closed at $8.34.

Analyst Ratings Changes

Several research analysts recently weighed in on RXRX shares. Needham & Company LLC restated a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Thursday, February 6th. KeyCorp decreased their price objective on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a report on Wednesday, January 8th. Cowen restated a “hold” rating on shares of Recursion Pharmaceuticals in a research note on Friday. Finally, Leerink Partners dropped their price target on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating on the stock in a research report on Friday. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, Recursion Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $8.25.

Recursion Pharmaceuticals Price Performance

The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The firm has a market cap of $2.93 billion, a P/E ratio of -4.91 and a beta of 0.86. The business’s fifty day simple moving average is $7.72 and its 200-day simple moving average is $7.08.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Friday, February 28th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.17). The firm had revenue of $4.60 million during the quarter, compared to the consensus estimate of $19.04 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. Recursion Pharmaceuticals’s revenue was down 57.8% compared to the same quarter last year. During the same quarter last year, the business posted ($0.42) earnings per share. As a group, analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in RXRX. Allspring Global Investments Holdings LLC purchased a new stake in shares of Recursion Pharmaceuticals in the third quarter worth $25,000. Private Advisor Group LLC raised its holdings in shares of Recursion Pharmaceuticals by 28.6% in the 3rd quarter. Private Advisor Group LLC now owns 15,419 shares of the company’s stock valued at $102,000 after acquiring an additional 3,432 shares in the last quarter. International Assets Investment Management LLC boosted its position in shares of Recursion Pharmaceuticals by 527.3% during the 3rd quarter. International Assets Investment Management LLC now owns 84,682 shares of the company’s stock valued at $558,000 after acquiring an additional 71,182 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Recursion Pharmaceuticals by 1,173.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 87,539 shares of the company’s stock worth $611,000 after purchasing an additional 80,664 shares in the last quarter. Finally, SteelPeak Wealth LLC increased its position in shares of Recursion Pharmaceuticals by 310.0% in the third quarter. SteelPeak Wealth LLC now owns 88,274 shares of the company’s stock worth $582,000 after purchasing an additional 66,742 shares during the last quarter. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.